Weekly Docetaxel, Cisplatin, and Cetuximab in Palliative Treatment of Patients with Squamous Cell Carcinoma of the Head and Neck.
CONCLUSION: Weekly docetaxel, cisplatin, and cetuximab is an effective regimen for patients with metastatic or recurrent SCCHN. Response rates, PFS, and OS compare favorably with other combination chemotherapy treatments. Grade 4 toxicity rates observed in this study were substantially lower than those described with regimens using less frequent, higher-dose chemotherapy schedules.
PMID: 29540603 [PubMed - as supplied by publisher]
Source: The Oncologist - Category: Cancer & Oncology Authors: Trieu V, Pinto H, Riess JW, Lira R, Luciano R, Coty J, Boothroyd D, Colevas AD Tags: Oncologist Source Type: research
More News: Cancer & Oncology | Carcinoma | Chemotherapy | Docetaxel | Erbitux | Lessons | Palliative | Skin Cancer | Squamous Cell Carcinoma | Study | Taxotere | Toxicology